chronic myeloid leukemia
Conditions
Interventions
three-month observation and then administration of oral citrate for three months
Sponsors
Keio University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients who have chronic myeloid leukemia. 2. Patients who are given imatinib mesylate at a daily dose of 300 - 400 mg for more than 6 months. 3. Patients who had muscle cramps more than eight times in three months. 4. Patients who go to Devision of hematology, Keio University Hospital. 5. Patients who agreed to participate this clinical trial, and signed to informed consent form.
Exclusion criteria
Exclusion criteria: 1. Patient who have severe renal impairment 2. Patients who take drugs inducing muscle cramps , such as statin, diuretic, analgesic, steroid, cyclosporine, vincristine or cisplatin, etc. 3. Patients who have diseases accompanied by muscle cramps, such as liver chirosis or diabetes mellitus, etc. 4. Patients who take drugs preventing or treating muscle cramps. 5. Patients who are considered as inappropriate to register by attending physicians
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| frequency of muscle cramps in three months with or without oral citrate | — |
Secondary
| Measure | Time frame |
|---|---|
| adverse event location of muscle cramps | — |
Countries
Japan
Contacts
Public ContactJun Kato
Keio University School of Medicine Division of Hematology
Outcome results
None listed